202 related articles for article (PubMed ID: 29133777)
1. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
2. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
[TBL] [Abstract][Full Text] [Related]
3. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
[TBL] [Abstract][Full Text] [Related]
4. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
5.
Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
[TBL] [Abstract][Full Text] [Related]
6. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
7. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].
Li ZZ; Wang YJ; Feng JK; Tan JB; Zhao RB; Yang TH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):695-699. PubMed ID: 32319419
[TBL] [Abstract][Full Text] [Related]
9. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
[No Abstract] [Full Text] [Related]
11. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
12. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
14. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
[TBL] [Abstract][Full Text] [Related]
15. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
[No Abstract] [Full Text] [Related]
17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
18. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
Roberts KG; Morin RD; Zhang J; Hirst M; Zhao Y; Su X; Chen SC; Payne-Turner D; Churchman ML; Harvey RC; Chen X; Kasap C; Yan C; Becksfort J; Finney RP; Teachey DT; Maude SL; Tse K; Moore R; Jones S; Mungall K; Birol I; Edmonson MN; Hu Y; Buetow KE; Chen IM; Carroll WL; Wei L; Ma J; Kleppe M; Levine RL; Garcia-Manero G; Larsen E; Shah NP; Devidas M; Reaman G; Smith M; Paugh SW; Evans WE; Grupp SA; Jeha S; Pui CH; Gerhard DS; Downing JR; Willman CL; Loh M; Hunger SP; Marra MA; Mullighan CG
Cancer Cell; 2012 Aug; 22(2):153-66. PubMed ID: 22897847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
